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Abstract 
 
Miniaturization is a hallmark of modern technologies. Notably, this feature has not spared 
molecular biology and its potential applications. Towards developing more effective 
therapeutics against cancer, studies began to explore more than a decade ago how natural 
tumor suppression could be translated into antineoplastic drugs. To this end, investigators 
focused on major constituents of a central pathway that protects cells against neoplastic 
transformation: the nuclear retinoblastoma protein (RB) pathway. As such, peptide mimetics 
of RB, p16 and p21 were developed. Likewise, the p53 and von Hippel-Lindau gene products 
which affect indirectly the RB pathway provided additional templates for the development of 
anti-proliferative peptides. Each of the peptides derived from these distinct tumor 
suppressors was made cell-permeable by its ligation to an amino acid sequence conferring 
cellular internalization. Details reviewed here reveal that through the application of such 
anti-cancer peptide therapeutics alone or in conjunction whenever synergy is to expect, the 
dark era of chemotherapy will likely be overcome, at last. 
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It is interesting that major insights within various scientific fields often display common 
features. The "helix" idea is a classic that has emerged both in the early studies by Pauling et 
al. dealing with protein structure and those subsequently investigating the nature of the 
gene. Another example that connects even more disparate areas is that concerning 
miniaturization. This principle of down-sizing while upholding or even surpassing the 
capabilities of a larger template- initially mainly reserved to the discipline of electronics, 
particularly to the design of ever smaller central processing units e.g. of those driving 
personal computers, ultimately resulting in tiny microchips- has meanwhile reached 
molecular biology, specifically the development of preclinical therapeutics. 
In this context, studies conducted more than a decade ago suggested that one could 
compress a given protein function into a much shorter peptide sequence. This idea then 
served as a basis for bold theoretical leaps according to which one could combine several 
such sequences, each embodying a different function, to create fusion polypeptides that, 
despite being much smaller than a functionally comparable protein, could substitute or even 
be superior to their parent molecules. One such avenue was outlined by synthetic inducible 
biological response amplifiers (SIBRAs), multi-functional polypeptides proposed to become 
activated upon appropriate cues and characterized by several features such as ligand binding, 
cellular internalization/nuclear translocation as well as DNA binding and trancriptional 
activation, ultimately ensuring an appropriate host response to the cue and gradually 
disappearing once the cue had vanished (1). 
Yet, it was soon realized that accomplishing SIBRAs may be a long way to go and, 
hence, the feasibility and efficacy of less complex synthetic peptides was addressed as a 
preliminary stage towards SIBRAs. It was at about the same time that the existence of a 
retinoblastoma protein (RB) pathway of central importance to tumor suppression and 
therefore inactivated in most human tumors was clearly established (2). This pathway mainly 
involves RB (or yet a relative thereof such as p107 or p130) and three types of proteins: a 
cyclin, a cyclin-dependent kinase (cdk) and an inhibitor of such kinase such as p16 and p21. 
Since cancer posed a formidable treatment challenge then as it still does now, the question 
arose whether the tumor-suppressive components of the RB pathway, i.e. RB, p16 and p21, 
could be imitated by much smaller artificial peptides which would thus be more suitable to be 
applied as drugs than the larger natural proteins serving as their templates. 
As far as human RB- a 928-amino acid protein- is concerned, coupling a 6-amino acid 
RB fragment with binding affinity for the LXCXE motif in growth-promoting proteins such as 
insulin and the E7 protein of human papilloma virus (HPV) 16 to a cellular internalization 
sequence- more precisely, a nuclear localization sequence-, resulted in a fusion polypeptide 
capable of inhibiting cell cycle progression (3,4) and, upon further modifications conferring 
protease resistance, cytotoxic to various human tumor cells in vitro (5). It was further 
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elucidated that the more precise mechanisms of action of these RB-derived peptides are an 
interference with insulin-RB dimerization (6,7) and the induction of highly elevated levels of 
intracellular p21 (8). Most intriguingly, however, is these peptides´ demonstrated in vivo 
antineoplastic activity against syngeneic mouse tumors (9) and human lung cancer 
xenografts in nude mice (10,11). 
As a variation on the RB peptide theme, it has more recently been shown that a 39-
amino acid peptide sequence present in the RB family protein pRb2/p130, if joined to an 
internalization sequence, yields a fusion polypeptide with in vitro and in vivo anti-tumor 
properties (12). 
Furthermore, proteins upstream from RB were equally explored towards the 
generation of anti-cancer peptide mimetics. Accordingly, a p16 peptide was designed, joined 
to a cell-penetrating sequence and such fusion polypeptide then shown to block the cell cycle 
progression of RB-positive cancer cells in vitro, yet not that of RB-negative malignant cells 
(13), reflecting the necessity for functional RB to be present if p16 (or a peptide derived 
therefrom) is to exert growth-inhibitory effects. This observation has also been confirmed in 
an in vivo experimental mouse model for human melanoma (14). Moreover, the cdk inhibitor 
p21 could also be translated into an active antineoplastic peptide (15).  
Last but not least, tumor suppressors such as p53 and the VHL gene product, 
respectively, which are known to employ RB as a downstream effector to interfere with 
oncogenesis equally served as templates for the design of anti-cancer peptides (16-18). 
However, after the "Golden Age" of cell-permeable tumor suppressor peptides 
between 1997 and 2003, this promising direction could not keep up the same fast pace 
mainly because of two reasons. 
Firstly, tyrosine kinases as drug targets had captured the attention of most anti-
cancer drug developers and their sponsors around the turn of millennium. Yet, despite the 
introduction of Bcr-Abl and HER2 inhibitors into the clinical therapy of cancer, a genuine 
breakthrough, especially in treating metastasis, is still beyond reach for such (non-peptide) 
drugs. 
In fact, as previously outlined within the framework of a cybernetics of cancer 
signalling (19), therapeutic blockade of (cell surface) tyrosine kinases is particularly prone to 
inducing resistance phenomena since such proteins are highly redundant for a cancer cell 
given that, in terms of signal transduction, they are located considerably upstream from the 
nucleocrine (20) and RB (2) pathways. This preceding view has just recently been confirmed 
once again by the necessity to employ a "cocktail" of several tyrosine kinase inhibitors in 
order to achieve antineoplastic effects (21). However, it has to be emphasized that, besides 
the peril of adverse drug interactions potentially arising from any combination regimen, even 
such "cocktails" will predictably entrain the emergence of significant resistance, in this case 
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specifically involving cytoplasmic proteins relaying (cell surface) tyrosine kinases to the key 
players in the nucleus, for instance by selecting for mutant PI3kinases displaying constitutive 
(oncogenic) activity (22). 
By contrast, interventions aimed at directly influencing the nucleocrine and RB 
pathways- located one step away from gene expression and thus representing a signal 
transduction level of minimal redundancy and maximal entropy, hence making resistance 
development rather unlikely- should represent a most promising therapeutic approach. It 
could be accomplished by cell-permeable RB pathway-derived tumor suppressor peptides 
entering not only cancer cells, but also non-malignant cells. 
This fundamentally novel proposal (23) to affect both types of cells in the same way- 
thus contradicting the current dogma of targeting just malignant cells while sparing normal 
cells- is crucial since such approach would globally counteract oncoprotein-driven metastasis 
and consequently prevent that neoplastic transformation proceeds at the (epi)genetic level in 
otherwise morphologically normal cells, for instance in normal cells adjacent to a breast 
carcinoma  (24). 
Secondly, maintaining a swift development rate for nuclear tumor suppressor-derived 
peptide therapeutics was further hampered by the long-standing and widespread fallacy 
according to which peptides per se are allegedly not good drugs. 
However, starting with Vincent du Vigneaud´s success story on the synthesis of 
oxytocin, a peptide to be later administered as a drug for the induction of labor, back in the 
1950s until today when the T20 peptide proved to be an efficient therapeutic against HIV 
infections, peptides have repeatedly underscored their great potential for direct usage as 
drugs. Yet, as often in the history of medicine, even the best treatment principles need 
individuals who champion their use, whether it was penicillin or are peptide drugs now, 
particularly given the latter´s exciting prospects one can certainly envisage (25). 
If cancer is to be effectively treated with cell-penetrating tumor suppressor peptides 
in the future, then, besides the option for single drug treatment, e.g. of RB-negative 
malignancies by means of RB-like peptides, one should also explore potential synergies 
between various such peptides. For instance, in the case of patients with RB-positive tumors, 
it would be interesting to investigate whether a potential efficacy of p16 peptides can be 
augmented by the addition of RB-derived peptides in an attempt to increase the quantity of 
functional RB proteins in situ to mediate p16 peptide-initiated antineoplastic effects. The 
ultimate challenge will be to achieve synergy between distinct tumor suppressor peptides at 
the expense of minimal or no adverse interactions between such candidate drugs while 
minimizing the emergence of resistance to therapy by combining several such peptide drugs. 
Though not a simple task, the journey back into the bright horizon of cell-permeable tumor 
suppressor peptides should be worth completing. 
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